HUP0202779A2 - Immunológiai eljárás szöveti transzglutamináz (tTG) elleni antitestek kimutatására, tTG alkalmazása diagnosztikai célokra és terápiás ellenőrzésre, valamint tTG-t tartalmazó orális gyógyászati hatóanyag - Google Patents

Immunológiai eljárás szöveti transzglutamináz (tTG) elleni antitestek kimutatására, tTG alkalmazása diagnosztikai célokra és terápiás ellenőrzésre, valamint tTG-t tartalmazó orális gyógyászati hatóanyag

Info

Publication number
HUP0202779A2
HUP0202779A2 HU0202779A HUP0202779A HUP0202779A2 HU P0202779 A2 HUP0202779 A2 HU P0202779A2 HU 0202779 A HU0202779 A HU 0202779A HU P0202779 A HUP0202779 A HU P0202779A HU P0202779 A2 HUP0202779 A2 HU P0202779A2
Authority
HU
Hungary
Prior art keywords
ttg
diagnosis
therapy
tissue transglutaminase
directed towards
Prior art date
Application number
HU0202779A
Other languages
English (en)
Inventor
Tobias Ehnis
Walburga Dieterich
Detlef Schuppan
Original Assignee
Walburga Dieterich
Detlef Schuppan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7801172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0202779(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Walburga Dieterich, Detlef Schuppan filed Critical Walburga Dieterich
Publication of HUP0202779A2 publication Critical patent/HUP0202779A2/hu
Publication of HUP0202779A3 publication Critical patent/HUP0202779A3/hu
Publication of HU228479B1 publication Critical patent/HU228479B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)

Abstract

A találmány tárgyát eljárások képezik ellenanyagok testfolyadékokbantörténő kimutatására, szöveti transzglutaminázzal (<tissuetransglutaminase<; tTG), annak antigén sajátságú struktúráival,immunreaktív szekvenciáival vagy analógjaival, valamint tTG-tartalmúvegyületekkel, azok antigén sajátságú struktúráival, immunreaktívszekvenciáival vagy analógjaival adott immunreakció alapján. Atalálmány tárgyát képezi tTG és a fenti vegyületek alkalmazásabetegségek diagnózisára és a terápia hatásosságának ellenőrzésére;előnyösen, krónikus gyulladásos betegségek vagy autoimmun betegségekdiagnózisára és terápiájuk hatásosságának ellenőrzésére; például<sprue< vagy <coeliakia< diagnózisára és terápiája hatásosságánakellenőrzésére. A találmány tárgyát képezik továbbá, szájon átadagolható gyógyászati hatóanyagok, amelyek aktív hatóanyagként tTG-t,tTG-tartalmú vegyületeket vagy azok részeit tartalmazzák, és amelyekalkalmasak immuntolerancia kiváltására. A találmány szerinti megoldásalkalmas tTG-vel kapcsolatos immunológiai rendellenességek dignózisáraés a terápiás hatékonyság ellenőrzésére. Ó
HU0202779A 1996-07-18 1997-07-14 Immunological process for detecting antibodies directed towards tissue transglutaminase (ttg), use of ttg for diagnostic purposes and therapy control, and oral pharmaceutical agent containing ttg HU228479B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19630557A DE19630557C2 (de) 1996-07-18 1996-07-18 Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Gewebe-Transglutaminase (tTG) sowie die Verwendung von tTG in Diagnose und Therapie
PCT/EP1997/003740 WO1998003872A2 (de) 1996-07-18 1997-07-14 IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG

Publications (3)

Publication Number Publication Date
HUP0202779A2 true HUP0202779A2 (hu) 2002-12-28
HUP0202779A3 HUP0202779A3 (en) 2009-07-28
HU228479B1 HU228479B1 (en) 2013-03-28

Family

ID=7801172

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202779A HU228479B1 (en) 1996-07-18 1997-07-14 Immunological process for detecting antibodies directed towards tissue transglutaminase (ttg), use of ttg for diagnostic purposes and therapy control, and oral pharmaceutical agent containing ttg

Country Status (22)

Country Link
US (2) US6319726B1 (hu)
EP (1) EP0912898B1 (hu)
CN (1) CN1138146C (hu)
AT (1) ATE210296T1 (hu)
AU (1) AU718797B2 (hu)
BR (1) BR9710500B1 (hu)
CA (1) CA2260769C (hu)
CZ (1) CZ291662B6 (hu)
DE (2) DE19630557C2 (hu)
DK (1) DK0912898T3 (hu)
ES (1) ES2131038T3 (hu)
GR (1) GR990300020T1 (hu)
HK (1) HK1021025A1 (hu)
HU (1) HU228479B1 (hu)
IL (1) IL128042A (hu)
NO (1) NO321466B1 (hu)
NZ (1) NZ333744A (hu)
PL (1) PL189091B1 (hu)
PT (1) PT912898E (hu)
SI (1) SI9720044B (hu)
SK (1) SK284410B6 (hu)
WO (1) WO1998003872A2 (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3596199A (en) * 1998-05-06 1999-11-23 Kobenhavns Universitet Treatment of celiac disease
WO2001001133A2 (en) * 1999-06-28 2001-01-04 Immundiagnostik Ag Diagnosis of gluten sensitive enteropathy and other autoimmunopathies
US6703208B1 (en) 1999-10-20 2004-03-09 Immco Diagnostics Immunological assay for detection of antibodies in celiac disease
AU1966201A (en) * 1999-10-20 2001-04-30 Immco Diagnostics Immunological assay for detection of antibodies in celiac disease
CU22968A1 (es) * 2000-06-07 2004-07-14 Ct Ingenieria Genetica Biotech Procedimiento para la detección de anticuerpos anti transglutaminasa con utilidad en el diagnóstico de la enfermedad celíaca
GB0103024D0 (en) * 2001-02-07 2001-03-21 Rsr Ltd Assay for Autoantibodies to tissue transglutaminase
FI20010868A0 (fi) 2001-04-25 2001-04-25 Markku Maeki Menetelmä ja välineet gluteenin indusoimien tautien havaitsemiseksi
KR100488131B1 (ko) * 2001-07-07 2005-05-06 (주)푸드바이오테크 알레르기 진단용 단백질 칩과 알레르기 유발원의 검출방법 및 알레르기 유발 항체의 검출 방법
GB0117870D0 (en) 2001-07-21 2001-09-12 Univ Nottingham Trent Method of diagnosis and kit of parts therefor
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
DE60336754D1 (de) * 2002-02-14 2011-05-26 Univ R Enzymbehandlung von nahrungsmitteln für zöliakie-sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
CA2487247A1 (en) * 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
EP1563300B1 (en) 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US20080038760A1 (en) * 2004-06-08 2008-02-14 Method For Decting Anti-Transglutaminase Antibodies Method for Detecting Anti-Transglutaminase Antibodies
US20090305303A1 (en) * 2006-07-25 2009-12-10 Cecile Besson Duvanel immunochromatography device for the diagnosis of diseases in a sample
ES2369544T3 (es) * 2007-01-26 2011-12-01 Ga Generic Assays Gmbh Procedimiento para la detección de anticuerpos en fluidos corporales mediante una reacción inmunitaria con glicoproteína 2 (gp2) de gránulos de zimogeno del páncreas para el diagnóstico diferencial de enfermedades inflamatorias del intestino y pancreatitis crónica.
US8778338B2 (en) * 2007-03-16 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
ATE511651T1 (de) 2007-04-06 2011-06-15 Zedira Gmbh Transglutaminase 6 als diagnostischer indikator für autoimmunerkrankungen
HU0900199D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis of gluten-induced autoimmune diseases
FR2949782B1 (fr) 2009-09-04 2015-10-16 Isp Investments Inc Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
JP6012767B2 (ja) 2012-02-07 2016-10-25 ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー 基板、ペプチドアレイ、および方法
PT2839290T (pt) 2012-04-17 2019-06-12 Aeneas Gmbh & Co Kg Processo para diagnóstico pré-sintomático de doença celíaca e sensibilidade ao glúten
DE102012007510A1 (de) 2012-04-17 2013-10-17 Aesku.Diagnostics GmbH & Co. KG Verfahren zur Präsymptomatischen Diagnostik von Zöliakie und Glutensensitivität
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
JP5981667B2 (ja) 2013-02-15 2016-08-31 ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー 増幅された電気化学発光検出のための方法および組成物
CN104090102B (zh) * 2014-06-13 2016-08-17 江南大学 冷冻鱼糜中微生物谷氨酰胺转胺酶elisa检测方法
AU2015314934A1 (en) 2014-09-10 2017-04-20 Vibrant Holdings, Llc Peptide microarrays and novel biomarkers for celiac disease
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
CN110055235A (zh) * 2019-05-14 2019-07-26 深圳市亚辉龙生物科技股份有限公司 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL155894B1 (en) * 1987-12-23 1992-01-31 Przed Zagraniczne W Polsce Pla Test for assessing gluten-dependent enteropathies
DE3829524A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von transglutaminasen als immunsuppressiva
DE19520480C2 (de) 1995-06-03 1997-04-30 Univ Leipzig Immunochemisches Testmaterial und Enzymimmunoassay zur Diagnostik von Zöliakie und verwandten Eiweißintoleranzen
US5716794A (en) * 1996-03-29 1998-02-10 Xybernaut Corporation Celiac antigen

Also Published As

Publication number Publication date
SK6799A3 (en) 2000-05-16
NO990190L (no) 1999-03-15
DE19630557C2 (de) 1998-07-02
EP0912898B1 (de) 2001-12-05
ES2131038T1 (es) 1999-07-16
AU718797B2 (en) 2000-04-20
US20020076834A1 (en) 2002-06-20
NZ333744A (en) 2000-03-27
DK0912898T3 (da) 2002-04-08
WO1998003872A2 (de) 1998-01-29
CA2260769A1 (en) 1998-01-29
BR9710500A (pt) 2000-01-18
IL128042A0 (en) 1999-11-30
CN1138146C (zh) 2004-02-11
DE59705683D1 (de) 2002-01-17
HU228479B1 (en) 2013-03-28
CA2260769C (en) 2005-09-06
HK1021025A1 (en) 2000-05-26
SK284410B6 (sk) 2005-03-04
HUP0202779A3 (en) 2009-07-28
BR9710500B1 (pt) 2009-05-05
IL128042A (en) 2007-06-17
CZ291662B6 (cs) 2003-04-16
ATE210296T1 (de) 2001-12-15
DE19630557A1 (de) 1998-01-29
SI9720044B (sl) 2003-02-28
PL189091B1 (pl) 2005-06-30
PT912898E (pt) 2002-05-31
GR990300020T1 (en) 1999-06-30
CZ11799A3 (cs) 1999-07-14
NO321466B1 (no) 2006-05-15
WO1998003872A3 (de) 1998-03-12
SI9720044A (sl) 1999-08-31
PL331203A1 (en) 1999-07-05
US6319726B1 (en) 2001-11-20
EP0912898A2 (de) 1999-05-06
ES2131038T3 (es) 2002-09-01
NO990190D0 (no) 1999-01-15
AU4201197A (en) 1998-02-10
CN1225723A (zh) 1999-08-11

Similar Documents

Publication Publication Date Title
HUP0202779A2 (hu) Immunológiai eljárás szöveti transzglutamináz (tTG) elleni antitestek kimutatására, tTG alkalmazása diagnosztikai célokra és terápiás ellenőrzésre, valamint tTG-t tartalmazó orális gyógyászati hatóanyag
EP1019072A4 (en) ASSISTANCE PROCESS FOR DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISM SYNDROME
BR0211474A (pt) Uso de tat de hiv-1 biologicamente ativa, fragmentos ou derivadas desta, para atingir e/ou ativar células apresentadoras de antìgeno, e/ou para disponibilizar moléculas carga para vacinação e/ou tratamento preventivo ou terapêutico de outras doenças
Plaisance et al. Effect of antipyretic therapy on the duration of illness in experimental influenza A, Shigella sonnei, and Rickettsia rickettsii infections
CA2263911A1 (en) Treatment of autoimmune diseases
HUP9904697A2 (hu) Eljárások és készítmények immunmodulációhoz
IT1220979B (it) Capsule contenenti un allergene e procedimento per la loro preparazione
ES2969532T3 (es) 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico
AU2010260585B2 (en) Compositions and methods for treatment of Multiple Sclerosis
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
Weary et al. Chronic urticaria in association with dermatophytosis: response to the administration of griseofulvin
Schröter et al. Juvenile dermatomyositis induced by toxoplasmosis
HUP0102853A1 (hu) Moraxella catarrhalis-ból származó vegyületek
Kerkhof The Woronoff zone surrounding the psoriatic plaque.
RU2237484C1 (ru) Способ лечения вич-инфицированных больных
Wrigley et al. Normal cerebral function with bilateral carotid occlusion.
McDougall et al. Lepromatous leprosy presenting with swelling of the legs.
Cornblath et al. Guillain-Barré syndrome
GB9617611D0 (en) Treatment of autoimmune disease
Governa et al. Autoantibodies in 16 patients with extensive burns and a review of the literature
RU2124349C1 (ru) Способ лечения неспецифических астено-невротических проявлений у лиц, работающих в условиях риска интоксикации тяжелыми металлами
RU1808328C (ru) Способ лечени острых кишечных инфекционных заболеваний
WO1995025531A1 (fr) Agent therapeutique contre les maladies auto-immunes et mode de traitement
RU94033679A (ru) Способ прогнозирования состояния иммунной системы новорожденного
Steiner et al. Clinical Quiz